Netflix (NASDAQ:NFLX): Pacific Crest writes that shares of Netflix should be bought on a post-earnings weakness, and expects to report Q1 subscriber growth at the upper half of the company’s guidance. The firm recommends owning the stock, and believes that the company’s margins may have risen 160 basis points.
Endo Health Solutions (NASDAQ:ENDP): Needham believes that the FDA will not force Opana ER generics out of the market, following the agency’s announcement that it isn’t approving generic versions of first-generation oxycontin. The firm maintains and Underperform rating on Endo shares, citing differences between the OxyCotin situation and Endo’s scenario with Opana.
Towers Watson (NYSE:TW) Stifel is excited about Watson’s OneExchange offerings for managing employee benefits, and expects the company to benefit from the growing rate of retirees who are receiving benefits. Stifel raised its price target from $71 to $84, and maintained its Buy rating.
InnerWorkings (NASDAQ:INWK): Barrington is viewing InnerWorking’s stock sell-off as a buying opportunity, and maintains its Outperform rating on its shares. The firm made note that the loss of Supervalu as a client was not due to performance issues, and the company has said that its new business pipeline is strong. The firm did lower its price target however, from $16 to $13.
Don’t Miss: Google: We Want Apple Back!